Drugs Medical

FDA approves gene therapy for treatment of high-risk bladder cancer

The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy for the treatment of high-risk bladder cancer.

Read More